health

Judge approves $7.25bn Bayer payout to settle claims that Roundup causes cancer

Judge approves $7.25bn Bayer payout to settle claims that Roundup causes cancer

German company faced 65,000 claims from people who said they developed cancer after using weedkiller A Missouri judge on Friday approved Bayer’s $7.25bn settlement of lawsuits ⁠alleging that its weedkiller ​Roundup causes cancer, potentially resolving litigation that has weighed on the German company for close to a decade. Judge Timothy Boyer of a state court in St Louis ⁠found the settlement “fair, reasonable and adequate”.

German company faced 65,000 claims from people who said they developed cancer after using weedkiller

A Missouri judge on Friday approved Bayer’s $7.25bn settlement of lawsuits ⁠alleging that its weedkiller ​Roundup causes cancer, potentially resolving litigation that has weighed on the German company for close to a decade.

Judge Timothy Boyer of a state court in St Louis ⁠found the settlement “fair, reasonable and adequate”.

He overruled objections that payouts to individual cancer victims would be too low because claimants who previously settled were paid more.

The judge also said delaying payouts could ⁠force victims, including those whose cancer is terminal, to wait “an indeterminate number of years” to be paid.

Bayer had faced approximately ​65,000 claims in US state and federal courts from ‌people who said they developed cancer ‌after using Roundup at home or on the job.

The settlement announced in February aimed to resolve nearly all current ‌and future Roundup claims in the US.

“The court’s final approval is a decisive milestone in the company’s strategy to mitigate the risks of both pending and future Roundup litigation,” Bayer’s CEO, Bill Anderson, said in a statement.

Bayer has faced extensive litigation over Roundup, and had seen its share price fall 46% since it bought Monsanto, which produces the weedkiller, for $63bn in 2018.

The company settled much of the Roundup litigation for $10.9bn in 2020, ‌but was unable to win court approval of a $1.25bn settlement to resolve future Roundup claims.

Bayer has long maintained that Roundup and its active ingredient glyphosate were safe, and that decades ​of studies had shown that glyphosate did not cause cancer.

The settlement was approved five months after the US supreme court overturned a $1.25m jury award for a Missouri man, John Durnell, who blamed years of exposure to glyphosate in Roundup for his non-Hodgkin lymphoma.

In a 7-2 decision, the court agreed with Bayer that a federal law regulating pesticides barred failure-to-warn claims brought under ⁠state law, undercutting a central pillar of many lawsuits.

Christopher Seeger, a lawyer for ​many of the plaintiffs, said the Durnell ​decision narrowed the ability of Roundup victims ​to pursue claims in court.

“We look forward to getting this relief into the hands of all ​Roundup victims as quickly ‌as possible,” he ​said in a statement.

Lawyers for ​some of the Roundup victims who objected to the settlement did not immediately respond to requests for comment.

The settlement excludes some lawsuits that remain pending in federal court. Bayer has said that about 200 of those cases were still being litigated, and that the supreme court decision gave it strong defenses.

  • judge
  • cancer
  • bayer
  • payout
  • claim
  • roundup
  • company
  • weedkiller

Summaries and tags are generated automatically. Stay informed with VidiaNews.

Related news

Pill to treat pancreatic cancer hailed as ‘biggest breakthrough in decades’
health

Pill to treat pancreatic cancer hailed as ‘biggest breakthrough in decades’

Cancer undetectable for one in 12 patients in daraxonrasib trial, while nearly all participants’ tumours stopped growing A pill that can shrink and potentially eliminate pancreas tumours is being hailed as the biggest breakthrough treatment for the cancer in decades. In one in 12 of the patients given the drug, daraxonrasib, during a trial, the cancer became undetectable, and the tumours stopped growing in almost all of the 61 patients.

Read →
Judge bans Trump’s restrictions on HIV funds for transgender patients
health

Judge bans Trump’s restrictions on HIV funds for transgender patients

The Trump administration cannot impose restrictions barring healthcare providers that receive certain federal HIV-treatment ⁠funds from acknowledging the gender identity ⁠of their transgender patients ​or from providing them with gender-affirming care, a federal judge ruled on Thursday. US district judge William Young in Boston sided with a group of national HIV medical associations and ⁠healthcare providers that challenged grant funding conditions imposed by the administration last year after Trump signed an executive order prohibiting federal funding for what he calls “gender ideology”.

Read →
Major changes in men’s tennis will take prize money for players to more than $350m
sports

Major changes in men’s tennis will take prize money for players to more than $350m

Major changes in men’s tennis will take prize money for players to more than $350m. Cash boost via creation of new ‘One Vision’ company More rest breaks to reduce player welfare issues The Association of Tennis Professionals (ATP) has approved major changes to the financial structure of men’s tennis that will see the total prize money available to the players increase to over $350m (£267m) by 2028 from $270m (£206m) this year. The creation of a new company to sell all the tour’s media, commercial and data rights, ATP Ventures, will lead to the investment of an additional $100m in player remune

Read →